Please assess the completion status of the following clinical trial:

Trial Title: PD of VAY736 in Patients With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Fulfilled revised European US consensus criteria for pSS~* ESSDAI value ≥ 6~* Elevated serum titers at screening of ANA (≥ 1:160)~* Seropositive at screening for anti-SSA and/or anti-SSB antibodies~* Stimulated whole salivary flow rate at screening of \> 0 mL/min~EXCLUSION CRITERIA:~- Prior or previous use of (specific dosages and intervals prior to study start may apply): B-cell depleting therapy (e.g., rituximab), Prednisone, anti-BAFF mAb, CTLA4-Fc Ig (abatacept), anti-TNF-α mAb, cyclophosphamide, azathioprine and medications known to cause dry mouth.~Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to randomization is allowed~* Active or recent history of clinically significant infection~* Vaccination within 2 month prior to study~* History of primary or secondary immunodeficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- VAY736 3 mg/kg (Type: EXPERIMENTAL): single dose iv of VAY736 at a dose of 3mg/kg
- VAY736 10 mg/kg (Type: EXPERIMENTAL): single dose iv of VAY736 at a dose of 10mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).